Enlivex Therapeutics Ltd.
ENLV
$1.04
-$0.06-5.46%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 48.35% | 30.30% | 17.22% | 13.52% | 6.41% |
| Total Depreciation and Amortization | -34.73% | -17.17% | -8.63% | 2.01% | 7.46% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -58.96% | 0.10% | 120.59% | -2.51% | 18.13% |
| Change in Net Operating Assets | 33.00% | 47.14% | 411.76% | 12.84% | -326.12% |
| Cash from Operations | 44.70% | 38.43% | 29.71% | 15.94% | 1.80% |
| Capital Expenditure | 56.36% | 97.33% | 97.61% | 98.40% | 97.09% |
| Sale of Property, Plant, and Equipment | 1,624.06% | 2,397.56% | 236.59% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 126.56% | 125.99% | 10.85% | 148.37% | -136.61% |
| Cash from Investing | 134.89% | 129.83% | 73.93% | 136.76% | -141.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,039.65% | 1,037.45% | 880.00% | 21.58% | 315.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -322.22% | -- | -- | 88.82% | -- |
| Cash from Financing | 1,692.78% | 1,342.50% | 1,105.61% | 35.41% | 140.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 105.10% | 101.49% | 101.82% | 79.45% | -226.88% |